Enhancing Antitumor Efficacy of MUC1 mRNA Nano-Vaccine by CTLA-4 siRNA-Mediated Immune Checkpoint Modulation in Triple Negative Breast Cancer Mice Model
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26178448 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Amir Monfaredan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran 1416634793, Iran. Hauptthemen laut MEDLINE: Mucin-1, RNA, Small Interfering, Cancer Vaccines, CTLA-4 Antigen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immunotherapy, particularly approaches that combine tumor-specific vaccines with immune checkpoint modulation, represents a promising strategy for overcoming tumor immune evasion. While most mRNA-based cancer vaccines focus solely on antigen delivery, there is a need for platforms that simultaneously enhance antigen presentation and modulate the tumor microenvironment to increase therapeutic efficacy. This study presents a novel dual-nanolipid exosome (NLE) platform that simultaneously delivers MUC1 mRNA and CTLA-4-targeted siRNA in a single system. These endogenous lipid-based nanoparticles are structurally designed to mimic exosomes and are modified with mannose to enable selective targeting to dendritic cells (DCs) via mannose receptors. The platform was evaluated both in vitro and in vivo in terms of mRNA encapsulation efficiency, nanoparticle stability, and uptake by DCs. The co-delivery platform significantly enhanced antitumor immune responses compared to monotherapies. Flow cytometry revealed a notable increase in tumor-infiltrating CD8+ T cells (p < 0.01), and ELISPOT assays showed elevated IFN-γ production upon MUC1-specific stimulation. In vivo CTL assays demonstrated enhanced MUC1-specific cytotoxicity. Combined therapy resulted in immune response enhancement compared to vaccine or CTLA-4 siRNA alone. The NLE platform exhibited favorable biodistribution and low systemic toxicity. By combining targeted delivery of dendritic cells, immune checkpoint gene silencing, and efficient antigen expression in a biomimetic nanoparticle system, this study represents a significant advance over current immunotherapy strategies. The NLE platform shows strong potential as a modular and safe approach for RNA-based cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran 1416634793, Iran.
- Department of Basic Oncology, Oncology Institute, Istanbul University, Istanbul 34093, Türkiye.
- Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran 1416634793, Iran.
- Department of Clinic Oncology, Oncology Institute, Istanbul University, Istanbul 34093, Türkiye.
- GeneDia Life Science Company, Tehran 1416634793, Iran.
- Department of Infectious Diseases and Clinical Microbiology, Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34093, Türkiye.
ORCID-Profile: Sena Şen, Alaviyehsadat Hosseininasab, Hamza Uğur Bozbey
Zitieren
APA
Monfaredan, A., Şen, S., Fathi, N. K., Taştekin, D., Hosseininasab, A., Bozbey, H. U., & Öncül, O. (2025). Enhancing Antitumor Efficacy of MUC1 mRNA Nano-Vaccine by CTLA-4 siRNA-Mediated Immune Checkpoint Modulation in Triple Negative Breast Cancer Mice Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178448
Vancouver
Monfaredan A, Şen S, Fathi NK, Taştekin D, Hosseininasab A, Bozbey HU, et al. Enhancing Antitumor Efficacy of MUC1 mRNA Nano-Vaccine by CTLA-4 siRNA-Mediated Immune Checkpoint Modulation in Triple Negative Breast Cancer Mice Model. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178448
BibTeX
@article{Monfaredan2025,
author = {Monfaredan, Amir and Şen, Sena and Fathi, Nahideh Karimian and Taştekin, Didem and Hosseininasab, Alaviyehsadat and Bozbey, Hamza Uğur and Öncül, Oral},
title = {Enhancing Antitumor Efficacy of MUC1 mRNA Nano-Vaccine by CTLA-4 siRNA-Mediated Immune Checkpoint Modulation in Triple Negative Breast Cancer Mice Model},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26178448}
}
EUVIMED